zilovertamab,ibrutinib
oncternal therapeutics,janssen,abbvie,merck
['zilovertamab', 'ibru', 'oncternal']
oncternal therapeutics presents rationale and plans for its registrational phase 3 study evaluating zilovertamab in combination with ibrutinib at the eha 2022 congress 
We provide a balanced view on small cap biotech equities.